Novo Nordisk/LinkedIn
Oct 31, 2025, 14:21
Novo Nordisk Submits Biologics License Application for Mim8 (Denecimig) in Hemophilia A
National Bleeding Disorders Foundation (NBDF) shared on LinkedIn:
”Novo Nordisk has submitted a Biologics License Application (BLA) for Mim8 (denecimig), a promising bispecific antibody therapy for people with hemophilia A, with or without inhibitors.
Mim8 may offer more flexible dosing options and an easier treatment experience through a single-use, prefilled injector pen.
Learn more about this milestone”
Read the full announcement here.
Stay updated on the emerging with Hemostasis Today.
-
Aug 19, 2026, 08:39Choosing the Right P2Y12 Inhibitor After PCI – JAMA Cardiology
-
Aug 19, 2026, 08:05Charles Cohen: Why Women Wait Years Longer for a Bleeding Disorder Diagnosis
-
Aug 19, 2026, 07:42Chukwuemeka Amarachi: Thalassemia – Types, Diagnosis and Management
-
Aug 19, 2026, 07:15Ajay Kumar: Real-World Outcomes of Plasma Exchange in NMOSD
-
Aug 19, 2026, 07:02Amer Zeidan: Managing Anemia in Lower-Risk MDS
-
Aug 19, 2026, 06:24GT Connect – Connecting the GT Community – Glanzmann’s Research Foundation
-
Aug 19, 2026, 01:43Elvira Grandone: Cancer and Thrombosis in Women – Where Do We Stand?
-
Aug 19, 2026, 01:37Ifeanyichukwu Ifechidere: Coagulation Knowledge – A Core Skill in Internal Medicine
-
Aug 19, 2026, 01:34Tommy Alfaro Moya: Celebrating a New Chapter Contribution in Clinical Hematology and Hemato-Oncology